Fig. 1: Vaccine effectiveness and 95% confidence intervals by time since vaccination.
From: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Vaccine effectiveness (presented as proportions out of 100 percentage points) and 95% confidence intervals of 2, 3, and 4 doses of monovalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes by time since vaccination among community-dwelling adults aged (A) 50–59 years, (B) 60–69 years, (C) 70–79 years, and (D) ≥ 80 years in Ontario, Canada, compared to unvaccinated adults (Note: Estimates were not reported if they were unstable [i.e., 95% confidence interval width exceeded 100 percentage points]). Please see Supplementary Table 10 for all estimates.
